An article published this year in “Biomaterials”
using one of our products, “FITC ANNEXIN V”, by our customers from the Research
Center Principe Felipe, Valencia, Spain, in the analysis of how Metabolomics
facilitates the discrimination of the specific anti-cancer effects of free- and
polymer-conjugated doxorubicin in breast cancer models. Congrats and Thanks.
Summay:
Metabolomics is
becoming a relevant tool for understanding the molecular mechanisms involved in
the response to new drug delivery systems. The applicability of this
experimental approach to cell cultures and animal models makes metabolomics a
useful tool for establishing direct connections between in vitro and in vivo data,
thus providing a reliable platform for the characterization of chemotherapeutic
agents. Herein, we used metabolomic profiles based on nuclear magnetic
resonance (NMR) spectroscopy to evaluate the biochemical pathways involved in
the response to a chemotherapeutic anthracycline drug (Doxorubicin, Dox) and an
N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-conjugated form (HPMA-Dox)
in an in vitro cell culture model and an in vivo orthotopic breast cancer model. We also used
protein expression and flow cytometry studies to obtain a better coverage of
the biochemical alterations associated with the administration of these
compounds. The overall analysis revealed that polymer conjugation leads to
increased apoptosis, reduced glycolysis, and reduced levels of phospholipids
when compared to the free chemotherapeutic drug. Our results represent a first
step in the application of integrated in vitro and in vivo metabolomic studies to the evaluation of drug
delivery systems.
Reference:
Product link:
FITC AnnexinV
No comments:
Post a Comment